comparemela.com

Lotta Ferm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mendus : Interim Report January - March 2024

English Swedish .

Erik mantingLotta fermNorthx biologics northLymphoma groupHuman research ethics committeeNorthx biologicsAustraliasian leukaemiaInnate killerAnnual innate killer cell summit

Mendus : Invitation to presentation of Mendus first quarter report 2024

Mendus : Invitation to presentation of Mendus first quarter report 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Lotta fermErik mantingFriday may

Mendus will participate in multiple investor and industry conferences in October and announces presentation of ALISON trial update at SITC

Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: LSX.

City ofUnited kingdomUnited statesSan diegoSan diego convention centerFrance generalCorey davisErik mantingMario brkuljLotta fermLeopold berteaLifesci advisorsSociety for the immunotherapy of cancerNordic congressValency communicationsCompany update

Mendus to participate in multiple investor and industry conferences in September

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: H.C. Wainwright 25th Annual Global Investment Conference New York, USA, September 11-13, 2023 Mendus CEO Erik Manting will participate and present a Company Update at the conference: https://hcwevents.com/annualconference/ Pareto Securities' Annual Healthcare Conference Stockholm, Swe

United statesNew yorkErik mantingCorey davisMario brkuljHans preustingLotta fermLifesci advisorsInternational cancer immunotherapy conferenceValency communicationsAnnual global investmentCompany updateOpening ceremonyNorthx innovationNasdaq stockholmSci advisors

Mendus AB: Mendus secures second shareholder loan from Van Herk Investments and reduces the number of outstanding convertible bonds with Negma Group

07.03.2023 - Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company has closed a second loan under the terms of the commitment from its largest shareholder Van Herk .

Mario brkuljErik mantingCorey davisLotta fermLifesci advisorsNegma groupValency communicationsChief financial officerVan herk investmentsAbuse regulationSci advisorsMendus ab

vimarsana © 2020. All Rights Reserved.